Montelukast Alvogen (Montelukast)

Montelukast selectively antagonizes the cysteinyl leukotriene receptor CysLT1 on airway smooth muscle and inflammatory cells. By blocking this receptor, it prevents leukotriene‑mediated bronchoconstriction, mucus production, and eosinophilic inflammation, thereby improving airflow and reducing allergic symptoms.

The appropriate dose of Montelukast Alvogen is determined by the prescribing clinician based on the patient’s age, condition, and response to therapy. Healthcare providers follow established guidelines and adjust the regimen as needed for optimal control.

Safety data for Montelukast in pregnancy are limited, so it should only be used if the potential benefit justifies the risk. During breastfeeding, the drug passes into milk in small amounts; clinicians should weigh maternal benefits against possible infant exposure.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients with aspirin‑exacerbated respiratory disease or those who prefer a non‑inhaled option, though it may be less potent for acute symptom relief.

Montelukast Alvogen should be stored at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture, direct sunlight and excessive heat to maintain stability.

Montelukast Alvogen is taken orally, usually once daily in the evening, with or without food. The tablet should be swallowed whole with a glass of water; it is not intended for crushing or chewing.

Serious risks include severe allergic reactions such as rash, angioedema, or anaphylaxis, as well as neuropsychiatric events like depression, suicidal thoughts, and mood changes. Patients should seek immediate medical attention if they experience any of these symptoms.

Montelukast Alvogen is contraindicated in individuals with known hypersensitivity to montelukast or any component of the formulation. Caution is advised for patients with severe liver disease, active psychiatric conditions, or those taking interacting medications without appropriate monitoring.